清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Biologic Treatments in Adolescents With Moderate-to-Severe Atopic Dermatitis: A Systematic Literature Review and Network Meta-analysis

医学 系统回顾 杜皮鲁玛 梅德林 重症监护医学 替代医学 循证医学 特应性皮炎 荟萃分析 皮肤病科 生物制剂 随机对照试验 儿科 过敏性 物理疗法 临床试验 循证实践
作者
Kevin H. Li,Emily K. Duffy,Jonathan Luong,Beth Devine
出处
期刊:Annals of Pharmacotherapy [SAGE Publishing]
卷期号:60 (10): 970-978 被引量:1
标识
DOI:10.1177/10600280251415369
摘要

BACKGROUND: Novel interventions, particularly biologic therapies, have been shown to be efficacious and safe in treating atopic dermatitis (AD) in adolescents. However, the comparative efficacy and safety of biologic interventions in adolescents with moderate-to-severe AD have not been explored. OBJECTIVE: To compare efficacy and safety measures in clinical trials of biologic interventions in adolescents aged 12 to 17 with moderate-to-severe AD. METHODS: MEDLINE, Embase, and trial registries were searched for double-blind, randomized placebo-controlled clinical trials assessing the efficacy of biologic therapies in adolescents with moderate-to-severe AD. Arm-level Bayesian network meta-analyses (NMAs) were performed and certainty of evidence was assessed through the Confidence in Network Meta-Analysis grading tool. Primary outcomes included the proportion of participants who achieved 75% improvement in Eczema Area and Severity Index score (EASI-75) and the proportion of participants who achieved 0 (clear) or 1 (almost clear) value on the Investigators' Global Assessment (IGA 0/1) at week 16. RESULTS: Four trials evaluating 3 drugs, dupilumab, lebrikizumab, and tralokinumab, representing 642 study participants were analyzed. Two dosing options were assessed for dupilumab and tralokinumab. Compared with placebo, the greatest effect was observed with dupilumab 200/300 mg every 2 weeks in both EASI-75 (risk ratio [RR]: 5.2; 95% credible interval [CrI]: 2.6, 12.0) and IGA 0/1 (RR: 12.0; 95% CrI: 3.3, 78.0). No differences were found between treatments. Certainty of the evidence was low. CONCLUSION AND RELEVANCE: Although there is some evidence that dupilumab may be more efficacious than lebrikizumab or tralokinumab, our findings suggest that there is no strong evidence of superiority of one treatment over another.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
null的应助被科研通管家采纳,获得10
3秒前
CipherSage的应助被TingtingGZ采纳,获得10
13秒前
zy997987876完成签到,获得积分10
16秒前
温婉的连虎完成签到,获得积分10
20秒前
21秒前
TingtingGZ发布了新的文献求助10
26秒前
26秒前
26秒前
李红莲完成签到,获得积分10
29秒前
31秒前
舒心谷菱完成签到,获得积分10
39秒前
Raju发布了新的文献求助10
41秒前
49秒前
vitamin完成签到 ,获得积分0
57秒前
1分钟前
喜悦的乐驹完成签到,获得积分10
1分钟前
漂亮秋荷完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
TingtingGZ完成签到,获得积分10
2分钟前
TingtingGZ发布了新的文献求助10
2分钟前
优美的烙完成签到,获得积分10
2分钟前
2分钟前
活力的尔蓉完成签到,获得积分10
2分钟前
2分钟前
2分钟前
A29964095完成签到 ,获得积分10
2分钟前
2分钟前
喷火球发布了新的文献求助100
2分钟前
开心的寄柔完成签到,获得积分10
2分钟前
blenx完成签到,获得积分10
2分钟前
3分钟前
迷路万天完成签到,获得积分10
3分钟前
3分钟前
3分钟前
隐形忆丹完成签到,获得积分10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173161
求助须知:如何正确求助?哪些是违规求助? 9565558
关于积分的说明 21780458
捐赠科研通 7767231
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555697
邀请新用户注册赠送积分活动 2476682